中华糖尿病杂志
中華糖尿病雜誌
중화당뇨병잡지
CHINESE JOURNAL OF DIABETES
2005年
1期
39-42
,共4页
罗四川%李启富%黄健康%汪志红%刘秀容%张素华%舒昌达
囉四川%李啟富%黃健康%汪誌紅%劉秀容%張素華%舒昌達
라사천%리계부%황건강%왕지홍%류수용%장소화%서창체
葡萄糖钳制技术%胰高血糖素%氢化可的松
葡萄糖鉗製技術%胰高血糖素%氫化可的鬆
포도당겸제기술%이고혈당소%경화가적송
Glucose clamp technique%Glucagon% Hydrocortisone
目的建立两步法高胰岛素-正常葡萄糖钳夹技术.方法应用两步法高胰岛素-正常葡萄糖钳夹术(第一阶段胰岛素输注速率为30 mU·m-2·min-1,第二阶段为120 mU·m-2·min-1),评估10名健康女性志愿者的胰岛素敏感性,同时监测钳夹试验过程中循环血内源性升糖激素(胰高血糖素、皮质醇、生长激素)和游离脂肪酸(FFA)浓度变化.结果(1)两步法高胰岛素-正常葡萄糖钳夹术第一阶段(60~90 min)和第二阶段(150~180 min)稳态血胰岛素分别维持在(46±7)mU/L和(218±27)mU/L,稳态葡萄糖利用率分别为(7.2±1.4)mg·kg-1·min-1和(13.1±1.2)mg·kg-1·min-1;(2)钳夹试验过程中,血清胰高血糖素、皮质醇和FFA水平较基础值均有显著下降,而生长激素和C肽水平无明显改变.结论成功建立了两步法高胰岛素-正常葡萄糖钳夹术;钳夹试验过程中高浓度的胰岛素抑制了胰高血糖素、皮质醇的分泌,并减少脂肪分解.
目的建立兩步法高胰島素-正常葡萄糖鉗夾技術.方法應用兩步法高胰島素-正常葡萄糖鉗夾術(第一階段胰島素輸註速率為30 mU·m-2·min-1,第二階段為120 mU·m-2·min-1),評估10名健康女性誌願者的胰島素敏感性,同時鑑測鉗夾試驗過程中循環血內源性升糖激素(胰高血糖素、皮質醇、生長激素)和遊離脂肪痠(FFA)濃度變化.結果(1)兩步法高胰島素-正常葡萄糖鉗夾術第一階段(60~90 min)和第二階段(150~180 min)穩態血胰島素分彆維持在(46±7)mU/L和(218±27)mU/L,穩態葡萄糖利用率分彆為(7.2±1.4)mg·kg-1·min-1和(13.1±1.2)mg·kg-1·min-1;(2)鉗夾試驗過程中,血清胰高血糖素、皮質醇和FFA水平較基礎值均有顯著下降,而生長激素和C肽水平無明顯改變.結論成功建立瞭兩步法高胰島素-正常葡萄糖鉗夾術;鉗夾試驗過程中高濃度的胰島素抑製瞭胰高血糖素、皮質醇的分泌,併減少脂肪分解.
목적건립량보법고이도소-정상포도당겸협기술.방법응용량보법고이도소-정상포도당겸협술(제일계단이도소수주속솔위30 mU·m-2·min-1,제이계단위120 mU·m-2·min-1),평고10명건강녀성지원자적이도소민감성,동시감측겸협시험과정중순배혈내원성승당격소(이고혈당소、피질순、생장격소)화유리지방산(FFA)농도변화.결과(1)량보법고이도소-정상포도당겸협술제일계단(60~90 min)화제이계단(150~180 min)은태혈이도소분별유지재(46±7)mU/L화(218±27)mU/L,은태포도당이용솔분별위(7.2±1.4)mg·kg-1·min-1화(13.1±1.2)mg·kg-1·min-1;(2)겸협시험과정중,혈청이고혈당소、피질순화FFA수평교기출치균유현저하강,이생장격소화C태수평무명현개변.결론성공건립료량보법고이도소-정상포도당겸협술;겸협시험과정중고농도적이도소억제료이고혈당소、피질순적분비,병감소지방분해.
Objective To establish a two-step hyperinsulinemic euglycemic clamp technique. Methods A two-step hyperinsulinemic euglycemic clamp (30 mU·m-2·min-1 and 120 mU·m-2·min-1) was established and applied to 10 nonobese healthy Chinese women with normal glucose (tolerance.) Results (1) During the clamp, the steady-state plasma insulin levels at the first step (6090min) and the second step (150180min) were(45.6±7.3)mIU/L and (217.8±27.2)mIU/L (respectively.) The steady-state glucose metabolism rates of the first step and the second step were (7.24±1.38) mg·kg-1·min-1 and (13.08±1.16) mg·kg-1·min-1 respectively. (2) During the two-step euglycemic clamp, there were significant decreases of serum cortisol, glucagon and free fatty acids compared with basal values while no significant changes occurred in serum growth hormone and C-peptide. Conclusion A two-step hyperinsulinemic euglycemic clamp was successfully established. During the clamp, the plasma insulin of high concentration inhibits lipid oxidation and the secretion of glucagon and cortisol.